Phacilitate Leaders World

Commercialisation

Commercialisation

Preparing for Commercialisation with the right CDMO

 

An interview with J. Kelly Ganjei, CEO and Chairman of Cognate Bioservices, Inc. 

Read the interview


 

The Small Biotech's Guide to Managing Partnerships

Susan Nichols, CEO of Falcon Therapeutics provides sharp insight and expertise on three different types of partnerships that are crucial for a small biotech's success in advanced therapies.

Find out more


 

Advanced Therapies 2025: the past, present and future of a ground-breaking industry

Cell and Gene therapies are an emerging form of healthcare that offer significant potential to improve the practice of medicine and provide benefits to patients who currently have limited or no treatment options. The complexity of these therapeutics poses challenges for scientists and firms developing these products, particularly as the industry looks to upscale manufacturing.

View video

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Anne-Virginie Eggimann
    bluebird bio
  • Great program, great people, great venue.
    Klaus Kühlcke
    EUFETS GmbH
  • Dynamic, interesting and highly interactive event that promotes exchange and networking in highly specialized field of gene therapy.
    Nathalie Clement
    Powell Gene Therapy Center, University of Florida
  • Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field.
    Dr James Trager
    Dendreon
  • It was all business. I’ve never been to an event where over 80% of the conversations I had were constructive to my business objectives.
    Kurt Gielen
    Chemelot Campus B.V.
  • Great way to expand network with global experts in cell and gene therapy who are facing similar challenges.
    Steven Goodman
    GSK